Cancer vaccine

Sequencio, a new Hong Kong unit of CK Life Sciences, is advancing about 20 cancer vaccine projects via China's faster pathway to human trials. CK Life Sciences vice-president and chief scientific officer Dr Melvin Toh Kean-meng said the firm plans investigator-initiated trials next year.